Up­dat­ed: Black­stone com­mits $300M to a for­mer Mer­ck an­ti­body for asth­ma, COPD

Black­stone’s next ma­jor bet is on a for­mer Mer­ck mon­o­clon­al an­ti­body for atopic der­mati­tis that a new biotech will test for asth­ma and COPD. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.